NLRP3 and chronic kidney disease: Other studies reported that febuxostat improved morning home blood pressure, had renal protective effects in CKD, and inhibited the NLRP3 inflammasome in vitro (Lin et al., 2019; Nomura et al., 2019; Hsu et al., 2020; Kario et al., 2021).